University of Wisconsin-Madison, Division of Pharmacy Professional Development

Get ready to dive into the latest interdisciplinary research on psychoactive substances at the University of Wisconsin-Madison! Explore groundbreaking studies, #network with experts, and discover how this cutting-edge research is shaping the future of #healthcare and pharmaceutical innovation. Don't miss out on this opportunity to broaden your knowledge and connect with leaders in the field. Let’s shape the future of psychoactive pharmaceutical science together! For more details, visit: https://lnkd.in/gzwG-qGp #PsychoactiveResearch #PharmacyInnovation #HealthcareSymposium #UWMadison #research #psychedelics #psychedelicscience #professionaldevelopment #psychoactivesubstances #psilocybin #pharmaceuticalscience

Fresenius Kabi and Formycon AG have announced the FDA approved ustekinumab-aauz (Otulfi) for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. Otulfi is a biosimilar referencing Johnson & Johnson’s ustekinumab (Stelara). #pharmaceuticalindustry #drugproducts #biosimilars #FDAapproval #stelara #crohnsdisease #ulcerativecolitis #plaquepsoriasis #psoriaticarthritis #biopharma

Vertex Pharmaceuticals is known for its cystic fibrosis drugs, but the company aims to diversify with a pipeline that reaches more therapeutic areas. CEO Reshma Kewalramani, MD FASN explained Vertex’s strategy during the World Medical Innovation Forum (Mass General Brigham Innovation) in Boston. Read on to learn more! #pharmaceuticalindustry #businessstrategy #diversification #innovation #pharmaceuticals #vertex #painmedication #celltherapy #cysticfibrosis #geneticdisease #type1diabetes #drugdevelopment

GSK announced positive data from a phase 3 trial that assessed the immunogenicity, reactogenicity, and safety of Arexvy (GSK), a respiratory syncytial virus (RSV) vaccine when co-administrated with Shingrix, a #shingles virus vaccine—both being adjuvant vaccines. #pharmaceuticalindustry #pharmaceuticals #immunization #vaccines #RSV #shinglesvaccine #respiratoryvirus #olderadults #diseaseprevention #research #adultimmunization

University of Wisconsin-Madison scientists are poised to gain a better understanding of how to treat a progressive scarring disease of the lungs that kills an estimated 40,000 people every year in the United States. University of Wisconsin-Madison School of Pharmacy Professor Seungpyo Hong is one of the interdisciplinary group of researchers working on pulmonary fibrosis under a new $11 million federal grant. #uwmadison #research #pharmaceuticalsciences #clinicalresearch #translationalresearch #transdisciplinaryresearch #pulmonaryfibrosis #ipf #lungscarring #imaging #drugdelivery #lungdisease #interdisciplinary

Positive results have been announced from a phase 3 trial evaluating the safety, tolerability and efficacy of veligrotug for the treatment of active thyroid eye disease (TED) in adults. Viridian Therapeutics, Inc. also said it has completed enrollment for a second phase 3 trial of veligrotug, THRIVE-2, and expects topline data to be available by the end of this year. #pharmaceuticalindustry #drugdevelopment #clinicaltrials #pharmaceuticals #thyroideyedisease #TED #clinicaldata #Ophthalmology #eyehealth

Roivant Sciences subsidiary Pulmovant is on track for a Phase 2 test of mosliciguat as a treatment for pulmonary hypertension associated with interstitial lung disease. The inhaled drug offers a different mechanism of action and less burdensome dosing compared to United Therapeutics Corporation’s blockbuster PH-ILD drug, Tyvaso. #pharmaceuticalindustry #drugdevelopment #clinicaltrials #pulmonaryhypertension #interstitiallungdisease #biopharma #bayer #rarediseases

NeOnc Technologies Holdings Inc navigates around the blood-brain barrier using drugs inhaled through the nose. With a lead program in mid-stage clinical testing of its intranasally administered brain cancer drug, NeOnc is now preparing to take itself public. #pharmaceuticalindustry #drugdevelopment #oncology #glioblastoma #braincancer #braincancertherapy #biopharma #clinicaltrials #intranasal #drugdelivery #bloodbrainbarrier #biotech

Eli Lilly and Company, Rivus Pharmaceuticals and more target different biological processes to generate higher-quality weight loss and avoid metabolic issues. Recent Phase Ib trial results showed strong weight reduction and a favorable tolerability profile for Zealand Pharma’s investigational amylin analog petrelintide. #pharmaceuticalindustry #weightloss #obesity #obesitytreatment #drugdevelopment #investigationaldrugs #GLP1drugs #weightmanagement #biopharma